Finding new ways of tackling disease
We're exploring what the medicines and consumer healthcare products of the future might look like, and how we can make them.
When it comes to choosing a healthcare product from the pharmacy or shop shelf you may be unaware that everyday shoppers are behind the creation and development of the products being purchased.
Today is World COPD Day. A day aimed at raising awareness of COPD, a chronic disease of the lungs, which affects around 329 million people worldwide.
Our immune system is a complex network of cells in our bodies that work together to protect us from harmful germs.
We think it’s about to get a whole lot smarter. In the dawning of the digital age, we’re exploring how the growing ‘internet of things’ can help us to bring digital, and all the opportunities that come with it, into our respiratory research, medicines and devices.
Scientists or detectives? Seeking new clues in COPD
GSK is using digital technologies and channels to improve the efficiency of our research, and to improve patient care.
Most of us will know someone who suffers from asthma and uses an inhaler regularly to control their condition.
Medical research relies on curious scientists to peer into cells through microscopes and to think on a molecular.
Turning the tide on antibiotic resistance.
Vaccine manufacture can take anywhere between 6 and 26 months.That’s not to mention the time required to research and develop a new vaccine, which can take up to 30 years.
Besides good timing and even better luck, it’s hard to pinpoint what it takes to be an innovator. Innovators tend to be creative, exceptionally persistent, and prepared to take calculated risks.
Scientists are discovering just how important microbes are in maintaining our respiratory health and immunity.
As recently as 30 years ago, tuberculosis (TB) was believed to be under control.
GSK’s Chief Immunology Officer discusses unlocking the secrets of the immune system to tackle disease
As science evolves we are learning that the immune system does so much more than protect us from an outside attack.
SXSW Interactive is a cutting edge technology and digital festival that brings together the brightest minds in emerging technology.
Our Bioelectronics R&D unit is pursuing a relatively new scientific field that could one day result in a new class of medicines that would not be pills or injections but miniaturised, implantable devices.
Bioelectronic medicine is a vision far from today’s medical practice. But we believe that one day, tiny devices, smaller than grains of rice, could be used to restore health in a range of chronic diseases centred on organs and biological functions.
A rare disease affects 1 in 2000 people or fewer.
We have a dedicated rare disease unit, with the ultimate goal of developing breakthrough solutions for people affected by rare diseases and delivering much needed medicines.
Innovative partnerships between science, business and charities could help tackle some of the most challenging healthcare issues, transforming the prospects of developing countries.
When extracted and purified, a compound from the soap bark tree can be mixed with other ingredients to create an ‘adjuvant’, turbocharging the body's immune defences.
Studies often employ state-of-the art technology to help scientists and doctors track the effect of a potential new medicine in patients’ bodies.
We have embarked on a pioneering new asthma remission study at the Centre for Therapeutic Target Validation.
The state-of-the-art facility where scientists are using cutting-edge technology to examine body and brain function.
A functioning immune system is crucial to our health. We have discovered that its role goes beyond such things as keeping colds at bay & fighting infections.
To be the best at what we do, we rely on innovative science to create products capable of transforming the lives of patients.
Learn how a new approach known as “bacteria-instructed synthesis” helps tackle bacterial infection.
If we can pinpoint a faulty gene and correct it, could we potentially find a way to cure genetic diseases?
Finding new ways to use biosensors and mobile health platforms to improve patient care.
Explore state-of-the-art facilities where scientists use cutting-edge technology to examine body and brain function.
What if instead of trying to see off the bugs, we harnessed them and made them work for us, instead of against us?
Find out how we are breeding 2,000 mosquitoes every week in the search for anti-malarial medicines.
We have a long-standing commitment to data transparency.
Learn how the Tres Cantos Open Lab offers top international scientists and academics the opportunity to pursue their own projects as part of an integrated team.
The number of people living with dementia worldwide is set to treble by 2050 to 135 million, according to the World Health Organization.
Martin Andrews leads our efforts to advance the treatment of rare diseases.
The way we design and carry out clinical trials is being turned on its head by the advent of the Salford Lung Study (SLS).
Dr Joe Cohen recalls his experiences of being part of the team to develop what could be the world’s first vaccine against malaria
Find out how our scientists have adapted an ingredient from a GSK mouthwash into a potentially life-saving gel for newborns in developing countries
By the time the second hand on your wristwatch has circled its dial, a child in Africa will have died of malaria.
Almost everyone in Tanzania is at risk of malaria. The mosquito-borne disease is responsible for more than 10% of deaths among children under five in this East African country.
The combination of increased funding, resources and education to fight malaria have contributed to a reduction in deaths from this mosquito-borne disease.
GSK responded to the crisis by contributing humanitarian support and accelerating the development of an investigational Ebola vaccine.
We are determined to use our resources, knowledge and expertise to help improve access to immunisation.
Lisa Bonadonna, head of the partnership at GSK, talks about a product innovation under development.
‘Thermostability’ - it may sound very technical and complicated, but really it’s all about fridges.
Learn how we are advancing the development of our GSK/NIH Ebola vaccine candidate.
Find out more about malaria and the life cycle of the parasites that cause it.
Patrick Vallance talks about how he went from leading an academic department to his current role heading up our R&D operations.
Helping midwives like Mary develop their skills and ensure more women give birth safely in Africa.
How can you fit six tablets into the same space as four – and why would you want to?
One of the more compelling aspects of scientific research is the unexpected avenues down which it can lead.
The first 48 hours of life can be critical for a newborn baby. Infections like pneumonia, contracted during a baby’s first two days, can prove fatal.
Our scientists aim to discover new medicines while reducing the environmental impact of their manufacture, supply and use.
Tijana Duric looks after the supply planning for albendazole in our neglected tropical diseases unit.
Fatiha describes her experience of polio and why she wanted to work for GSK.